Search clinical trials for: Adrenergic beta-1 Receptor Agonists

Total 11467 results

GlaxoSmithKline

Completed

A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

Irritable Bowel Syndrome (IBS)

United States
Dr. Glenio Mizubuti (MD, MSc)

Recruiting

Improving Tissue Oxygenation in Breast Reconstruction Surgery

Perioperative Tissue Oxygenation

Canada
Clinical Hospital Center Zemun
Military Medical Academy, Belgrade, Serbia; Institute for cardiovascular diseases... and other collaborators

Completed

Timing of Complete Revascularization for Multivessel Coronary Artery Disease in STEMI (MVD)

Myocardial Infarction

Serbia
McGill University Health Centre/Research Institute...
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie... and other collaborators

Unknown

Intraoperative Dobutamine Stress Test With Speckle Tracking to Decrease Postoperative Mortality (ISTMO) (ISTMO)

Mortality After Major Non Cardiac Surgery

Canada
Bispebjerg Hospital
Hormone Laboratory, Aker University Hospital, Oslo, Norway

Unknown

Concentrations of Salmeterol in Blood and Urine

Asthma

Denmark
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Comparison of Echocardiographic Techniques in Diagnosis of Coronary Artery Disease

Coronary Disease

United States
University of Abuja
Micronova Pharmaceuticals Ind Ltd

Completed

To Determine the Effect of Nebivolol on Office Blood Pressure of Blacks Residing in Nigeria (Nevibolol)

Hypertension

Nigeria
University Hospital Muenster

Completed

Myocardial Perfusion and Contractile Reserve in End-stage Renal Disease

Cardiovascular Diseases | End-Stage Renal Disease
Pontificia Universidad Catolica de Chile

Completed

Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients

Septic Shock

Chile
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle

Heart Diseases | Coronary Disease

United States
Shanghai Zhongshan Hospital

Recruiting

The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients

Cardiac Surgery | Cardiac Output

China
University of Nebraska

Completed

Pre-operative Evaluation of Kidney & Pancreas Transplant Patients

Kidney Transplantation | Pancreas Transplantation

United States
University of Sao Paulo

Completed

Liberal Versus Restrictive Use of Dobutamine in Cardiac Surgery (DOBUTACS)

Coronary Disease | Cardiac Output, Low

Brazil
Adelina Pellicer

Completed

Dobutamine Versus Placebo for Low Superior Vena Cava Flow in Newborns

Hemodynamic Instability

Spain
Université de Sherbrooke

Withdrawn

Stress Echocardiography Versus Coronary Angiography for Left Main Stenosis Detection (ESTRIE-TC)

Left Main Coronary Artery Disease | Stenosis

Canada
Indiana University
Office of Naval Research (ONR)

Completed

MIrabegron and Physiological Function in Cold Environments

Resting Energy Expenditure | Brown Adipose Tissue | Thermogenesis

United States
Indiana University
Office of Naval Research (ONR)

Completed

Mirabegron and Physiological Function in Cold Environments

Resting Energy Expenditure | Brown Adipose Tissue | Thermogenesis

United States
Astellas Pharma China, Inc.

Completed

A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

Pharmacokinetics of Mirabegron | Food Effect | Healthy Chinese Subjects

China
Swiss Group for Clinical Cancer Research

Completed

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

Switzerland
CHU de Quebec-Universite Laval

Completed

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder (Mirabegron)

Overactive Bladder | Urinary Incontinence
Astellas Pharma Inc

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder

Urinary Bladder, Overactive

Japan
Henning Bundgaard
Hvidovre University Hospital; Herlev Hospital; Royal North Shore Hospital; Bispebjerg-Frederiksberg... and other collaborators

Completed

Beta 3 Agonist Treatment in Heart Failure-2 (BEAT-HF II)

Heart Failure With Reduced Ejection Fraction NYHA Class III-IV

Denmark
Far Eastern Memorial Hospital

Withdrawn

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Taiwan
Seoul National University Hospital

Unknown

MIrabegron With oveRACtive bLadder Symptoms in mEn

Overactive Bladder

Korea, Republic of
AstraZeneca

Completed

Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men (AZD3199MAD)

Healthy Volunteers

Sweden
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Overactive Bladder

Poland, United Kingdom, Germany, Spain, Netherlands, Belgium, Czech Republic, Italy, Norway, Hungary, Sweden, Denmark, Greece, France, Russian Federation
Astellas Pharma Inc

Completed

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Theodore R. Brown, MD MPH
Astellas Pharma Inc

Completed

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis (MIRROR)

Multiple Sclerosis

United States
Baylor College of Medicine

Completed

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

Ureteral Obstruction | Flank Pain

United States
Buddhist Tzu Chi General Hospital

Completed

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Urinary Incontinence | Overactive Bladder Syndrome
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Taiwan
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Otto Muzik

Unknown

Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young Adults (MiraBAT)

Brown Fat

United States
Astellas Pharma Inc

Completed

A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Japan
AstraZeneca

Completed

Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma

Asthma

Sweden
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Mechanisms for Activation of Beige Adipose Tissue in Humans

PreDiabetes

United States
Astellas Pharma China, Inc.

Completed

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Urge Incontinence | Overactive Bladder (OAB)

China
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Philadelphia Urosurgical Associates
Astellas Pharma Global Development, Inc.

Terminated

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis (MirabegronIC)

Cystitis, Interstitial

United States
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES)

Urinary Bladder, Overactive

United States, Canada
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Astellas Pharma Inc

Completed

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Lower Urinary Tract Symptoms | Bladder Outlet Obstruction

United States, Canada
Astellas Pharma Inc

Completed

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
James J. Peters Veterans Affairs Medical Center
Kessler Foundation

Completed

The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury

Cerebral Blood Flow | Blood Pressure | Cognitive Function | Spinal Cord Injury | Autonomic Dysreflexia | Baroreceptor Integrity | Sympathetic Integrity | Vagal Integrity | Hypotensive | Autonomic Integrity

United States
Rigshospitalet, Denmark
Novo Nordisk A/S; Simon Spies Fonden; Helge Peetz og Verner Peetz og hustru Vilma...

Recruiting

Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock (DOBERMANN)

Acute Myocardial Infarction | Cardiogenic Shock

Denmark
The Royal Wolverhampton Hospitals NHS Trust

Completed

Novel Echocardiographic and Invasive Haemodynamic Measurements in the Assessment of Patients Low Flow Low Gradient Aortic Stenosis Undergoing TAVI (LFLG)

Cardiovascular Abnormalities

United Kingdom
Yale University
National Heart, Lung, and Blood Institute (NHLBI)

Withdrawn

Integrated RF and B-mode Deformation Analysis for 4D Stress Echocardiography

Coronary Artery Disease
Betaliq, Inc.
Trial Runners, LLC; Summit Analytical, LLC

Completed

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States

Search clinical trials for: Adrenergic beta-1 Receptor Agonists

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations